Drug-Device Combination -Top 5 Unknown Facts

Drug-Device Combination: How the Market is Shaping up?

The healthcare sector is in constant search for easier procedures that would also take less time to administer. Knowing that the healthcare sector is all about precision, such development in technologies is no surprise. But how far it can impact? Physicians who treat patients with cardiac irregularities, cancer, and other chronic diseases can answer this question perfectly. It is all about timing. Treating patients within the golden hour of the demand can be cumbersome and there, such drug-device combinations can extend the chances of saving lives by adding a few extra seconds. Pharmaceutical companies have realized this well. That is why they are investing a lot in developing new methods.

So, What Are These?

The Drug-Device Combination is a type that is the outcome of the idea of combination products that first got approved by the FDA in the 1970s. Since then, constant changes have been implemented to develop better products that can bring in more efficiency in the treatment. These drug-device combinations often come in as a single entity that has been fused together either physically or chemically. It can also come as co-packed or kitted, and in different packs with a label mentioning how to use them together. In 2002, the Office of Combination Products (OCP) came into being owing to which the drug-device combinations are now well-formed and on a track with significant guidance.  

What is the Present Industrial Scenario?

Recent guidelines published by the European Medicines Agency (EMA) dealt with the marketing authorization or post-authorization application. This would impact the drug-device combination market overview. This guideline has its focus on the applicable standards, information that should be on the package regarding description, drug composition, and others, information regarding potential contamination to make the use of it safer. The board also includes several other market guidelines to make sure that its impact becomes holistic. Its aim is to make the practice more transparent and consistent.

What’s New?

Plans to innovate in the field are always on. A few of those are in the pipeline. For instance, in November 2019, Ivy Brain Tumor Center from the Barrow Neurological Institute and SonALAsense have inked a deal to make sure that they develop a new test that would be non-invasive for sonodynamic therapy (SDT). In December 2019, Tusker Medical, Inc. announced that they have a new product called the Tula System that got called approval from the FDA. In November 2019, Idorsia announced a deal with Antares Pharma, Inc where they would try to develop a drug called selatogrel that would work well with Antares QuickShot auto-injector. The former is preparing for a Phase 3 study of the drug-device combination.

Take on the Market 

These innovations are going to be a big deal for the global drug device combination market. A detailed look into the drug device combination industry growth analysis would reveal that there is a chance that the drug device combination market size would increase with players taking expansion route. One of the major reasons that can play in its favor is the new form that often allows patients to have it self-administered. In fact, a lot of them are in the pipeline waiting for FDA’s approval. With both physicians and patients preferring this drug-device combination, the market can expect more innovations.